PIKfyve inhibition and involvement in cancer immunotherapy

06262024 - SLAP PIKfyve Paper - Ariana Tang.pdfPIKfyve inhibition and involvement in cancer immunotherapy

PIKfyve inhibition and involvement in cancer immunotherapy Ariana Tang, Grade 12, TOPS at Bloor Collegiate Institute Summary PIKfyve inhibition has led to a wide variety of implications of cancer treatment. Studying PIKfyve has led to a prominent discovery to improve cancer patients’ reactions to immunotherapy treatment—a non-invasive fashion of alleviating cancer conditions. Targeting the PIKfyve gene has been found to enhance major histocompatibility complex class I (MHC-I) and CD8+ T cell activity, improving immunotherapy efficacy. Furthermore, PIKfyve negatively regulates dendritic cells  (DCs) function through suppression of the NF-kB pathway. PIKfyve deletion in DCs, or treatment with Pikfyve inhibitor apilimod enhances DC-dependent T cell immunity reducing tumor growth. This paper summarizes PIKfyve function in the body and its implications in treating disease. Text